Silvain C, Breux J P, Grollier G, Rouffineau J, Becq-Giraudon B, Beauchant M
Service d'Hépato-Gastroentérologie, CHU Jean-Bernard, Poitiers.
Gastroenterol Clin Biol. 1989 Apr;13(4):335-9.
The aim of this study was to determine the efficacy of oral antibiotics in the treatment of severe infections in cirrhosis. Twenty-two patients (17 males, 5 females) with spontaneous bacteremia (n = 7) or bacterial peritonitis (n = 15) were treated with oral pefloxacin 400 mg per 24 hr alone (n = 1) or in combination with another oral antibiotic, trimethoprimsulfamethoxazole (n = 13), amoxicillin (n = 6), cefadroxil (n = 2), or metronidazole (n = 1). In patients with spontaneous bacteremia, all organisms were found to be sensitive to oral antibiotics, and a favorable response was elicited in 6 out of 7 (86 p. cent) within 3 days (mean) of treatment. In patients with spontaneous peritonitis, ascitic fluid cultures were positive in 11 cases, and organisms were sensitive to pefloxacin in 9 out of 11 cases. A favorable response was elicited in 13 out of 15 within 2 to 8 days of treatment. Fourteen patients died (64 p. cent), 3 of infection (bacteremia n = 1, peritonitis n = 2), and 11 patients of causes unrelated to infection, mainly variceal hemorrhage, hepatorenal syndrome or hepatocellular carcinoma, although the clinical symptoms of infection were controlled. One-year survival was 57 p. cent in patients with bacteremia and 33 p. cent in those with bacterial peritonitis. Oral treatment was well tolerated in all patients. We suggest that most bacteremia and spontaneous bacterial peritonitis in cirrhotic patients can be treated with oral antibiotics. In some patients, this may be accomplished on an out patient basis.
本研究旨在确定口服抗生素治疗肝硬化严重感染的疗效。22例患者(17例男性,5例女性)患有自发性菌血症(n = 7)或细菌性腹膜炎(n = 15),单独接受每24小时口服400 mg培氟沙星治疗(n = 1),或与另一种口服抗生素联合治疗,其中与甲氧苄啶 - 磺胺甲恶唑联合治疗(n = 13)、与阿莫西林联合治疗(n = 6)、与头孢羟氨苄联合治疗(n = 2)或与甲硝唑联合治疗(n = 1)。在患有自发性菌血症的患者中,发现所有病原体均对口服抗生素敏感,并且在治疗的3天(平均)内,7例中有6例(86%)出现了良好反应。在患有自发性腹膜炎的患者中,11例腹水培养呈阳性,11例中有9例病原体对培氟沙星敏感。在治疗的2至8天内,15例中有13例出现了良好反应。14例患者死亡(64%),3例死于感染(菌血症1例,腹膜炎2例),11例死于与感染无关的原因,主要是静脉曲张出血、肝肾综合征或肝细胞癌,尽管感染的临床症状得到了控制。菌血症患者的1年生存率为57%,细菌性腹膜炎患者的1年生存率为33%。所有患者对口服治疗耐受性良好。我们建议,肝硬化患者的大多数菌血症和自发性细菌性腹膜炎可以用口服抗生素治疗。在一些患者中,这可以在门诊基础上完成。